About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

have become a popular alternative for patients seeking GLP-1 prescriptions. “So generally speaking, on the FDA drug shortage ...

Millions more senior citizens and lower-income Americans could obtain coverage for costly anti-obesity drugs under a proposal ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

In 2024, coverage for obesity drugs increased to 44% among employers with 500 or more workers, compared to 41% last year, the ...